BeiGene Starts China Clinical Trial of PD-1 Candidate

BeiGene has dosed its first patient in a China Phase I trial of BGB-A317, a PD-1 treatment for cancer. The trial will enroll patients with solid tumors. BGB-A317 has already been administered to patients in Australia, New Zealand, the US and Taiwan. In the US, it is also being tested with another BeiGene cancer drug, BGB-3111, a small molecule BTK inhibitor in patients with B-Cell lymphoid malignancies. Located in Beijing, BeiGene has four molecularly-targeted and immuno-oncology drug candidates undergoing clinical trials in China, the US and elsewhere. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //